MET and neoplasm: At the protein level, co-expression of VEGFR2 and other receptor tyrosin kinases (RTKs) such as EGFR and MET, expressed on endothelial and tumor cells, respectively, has been associated to aberrant VEGF-A expression and intrinsic resistance to BEVA [12].